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Abstract: High levels of plasma triglycerides (TG) are a risk factor for cardiovascular diseases, 
often associated with anomalies in other lipids or lipoproteins. Hypertriglyceridemia (HTG), 
particularly at very high levels, significantly increases also the risk of acute pancreatitis. Thus, 
interventions to lower TG levels are required to reduce the risk of pancreatitis and cardiovas-
cular disease. Several strategies may be adopted for TG reduction, including lifestyle changes 
and pharmacological interventions. Among the available drugs, the most commonly used for 
HTG are fibrates, nicotinic acid, and omega-3 polyunsaturated fatty acids (usually a mixture of 
eicosapentaenoic acid, or EPA, and docosahexaenoic acid, or DHA). These last are available 
under different concentrated formulations containing high amounts of omega-3 fatty acids, 
including a mixture of EPA and DHA or pure EPA. The most recent formulation contains a 
free fatty acid (FFA) form of EPA and DHA, and exhibits a significantly higher bioavailability 
compared with the ethyl ester forms contained in the other formulations. This is due to the fact 
that the ethyl ester forms, to be absorbed, need to be hydrolyzed by the pancreatic enzymes 
that are secreted in response to fat intake, while the FFA do not. This higher bioavailability 
translates into a higher TG-lowering efficacy compared with the ethyl ester forms at equivalent 
doses. Omega-3 FFA are effective in reducing TG levels and other lipids in hypertriglyceri-
demic patients as well as in high cardiovascular risk patients treated with statins and residual 
HTG. Currently, omega-3 FFA formulation is under evaluation to establish whether, in high 
cardiovascular risk subjects, the addition of omega-3 to statin therapy may prevent or reduce 
major cardiovascular events.
Keywords: omega-3 fatty acids, eicosapentaenoic acid, docosahexaenoic acid, 
hypertriglyceridemia
Introduction
High levels of plasma triglycerides (TG) represent a risk factor for atherosclerosis 
and related cardiovascular diseases,1–3 although several contrasting observations have 
been reported. In fact, increased TG levels usually associated with decreased high-
density lipoproteins (HDL) cholesterol levels and increased small, dense low-density 
lipoprotein (LDL) particles;4 thus, the relation between hypertriglyceridemia (HTG) 
and coronary heart disease risk may be indirect, reflecting other risk factors associ-
ated with elevated TG. Accordingly, the relevant correlation of TG levels with an 
increased risk of coronary artery disease (CAD) was abolished after adjustment for 
HDL and non-HDL-cholesterol (that represents the marker of cholesterol content in 
all proatherogenic lipoproteins).5 Despite these controversies, it is well established 
that severe HTG, defined as TG levels $500 mg/dL ($5.65 mmol/L) significantly 
increases the risk of acute pancreatitis.6,7
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Elevated TG per se are probably not directly atherogenic; 
their role is most probably related to their association with 
atherogenic lipoproteins and apolipoprotein CIII (apoC-III), 
as suggested by the lack of cardiovascular disease in people 
with extreme TG plasma levels on one side and the role of 
remnants on the other.8,9 Under normal circumstances, TG 
are mainly transported by TG-rich lipoproteins such as the 
liver-derived very low-density lipoproteins (VLDL), while 
intestine-derived chylomicrons and their remnants predomi-
nate in some forms of HTG, such as familial hyperchylomi-
cronemia and hyperlipoproteinemias types III and V. Both 
VLDL and chylomicrons provide fatty acids to tissues by 
the action of lipoprotein lipase (LPL) present on the luminal 
surface of capillary endothelial cells.10 The activity of LPL 
requires several cofactors; among them, apolipoprotein CII 
(apoC-II) is an essential activator of LPL activity, while 
apoC-III is an LPL-inhibitor.10 Following LPL-mediated 
hydrolysis of TG to free fatty acids (FFAs), VLDL and chy-
lomicron remnants are formed, and are then cleared by the 
liver.10 Remnant lipoproteins may be atherogenic, and their 
levels are increased in subjects with HTG.11,12 In addition, 
high TG levels are associated with an increase of circulating 
small dense proatherogenic LDL.11 This is due to the fact 
that, under hypertriglyceridemic conditions, TG-rich lipo-
protein metabolism shifts from an apoE-dominated system, 
characterized by rapid clearance of VLDL from circulation, 
to an apoC-III-dominated system, characterized by reduced 
clearance of TG-rich lipoproteins and a preferential conver-
sion into small dense LDL.13
HTG has a direct impact on lipoprotein composition and 
metabolism; in fact, increased VLDL TG activates choles-
teryl ester transfer protein, thus resulting in the enrichment 
of HDL and LDL with TG, that in turn are hydrolyzed by 
the hepatic TG lipase, thus producing small dense HDL and 
LDL,6 a typical finding in HTG. TG-enriched HDL become 
dysfunctional and lose several of their antiatherogenic 
properties while small dense LDL are more susceptible to 
oxidation, and thus represent forms of proatherogenic lipo-
proteins, whose increase may raise the risk of cardiovascular 
disease.6 In addition, TG-rich lipoproteins are themselves 
proatherogenic and are involved in several proatherosclerotic 
processes, including the induction of endothelial dysfunction 
and activation, as well as inflammation and apoptosis6 in the 
arterial wall.
HTG is a well established common cause of acute pancre-
atitis, accounting for up to 10% of all cases of pancreatitis,14 
Both genetic and secondary disorders of lipoproteins asso-
ciate with hypertriglyceridemic pancreatitis; pancreatic 
lipase-induced hydrolysis of TG and subsequent formation 
of FFA trigger inflammation and seem to be involved in the 
development of HTG-induced pancreatitis. Very high levels 
of TG (.1,000 mg/dL, 11.3 mmol/L) significantly increased 
the risk of pancreatitis, but more moderate increases of TG 
(177–885 mg/dL, 2–10 mmol/L) may be usually present dur-
ing the early phases of acute pancreatitis.14 Several studies 
have also observed that the severity of pancreatitis is higher 
in subjects with HTG-induced pancreatitis compared with 
those with pancreatitis from other causes, with a higher 
frequency of complications, including renal failure, shock, 
and infections.15–17
Usually TG levels are classified as normal (,150 mg/
dL; ,1.7 mmol/L), borderline high (150–199 mg/dL; 1.7–
2.25 mmol/L), high (200–499 mg/dL; 2.26–5.6 mmol/L), 
or very high ($500 mg/dL; $5.65 mmol/L).6 HTG may 
result either from an increased TG production or a reduced 
TG elimination, and may have different causes, includ-
ing genetic disorders of TG metabolism (LPL deficiency, 
apoC-II deficiency, genetic variants of APOC3 and APOA5, 
familial combined hyperlipidemia, familial HTG, and 
dysbetalipoproteinemia).6,18,19 Acquired disorders of metabo-
lism, drugs (estrogens, steroids, and bile acid resins), dietary 
habits (marked alcohol consumption and high fat ingestion), 
and medical conditions, including poorly controlled diabetes 
and nephritic syndrome,6,18–20 can also contribute. The risk of 
acute pancreatitis is significantly higher in the presence of 
TG levels above ~880 mg/dL (10 mmol/L), although it may 
develop even with TG levels between 440 and 880 mg/dL 
(5–10 mmol/L); thus, lifestyle changes and pharmaco-
logical interventions may be required to reduce the risk of 
pancreatitis.21 In the presence of TG levels 200–500 mg/dL 
(2.26–5.65 mmol/L), TG lowering is recommended to 
reduce the cardiovascular risk.21 Several therapeutic strat-
egies to lower TG levels are available, and they must be 
always associated with changes of dietary habits (restric-
tion of calories, reduction of fat ingestion, and alcohol 
abstinence). The available pharmacological interventions 
to lower TG levels include statins, fibrates, nicotinic acid, 
and omega-3 polyunsaturated fatty acids.21 Here we shall 
discuss the role of omega-3 fatty acids, focusing on the 
recent data on the FFA form.
Overview of omega-3 fatty acids 
and mechanisms of action
Omega-3 polyunsaturated fatty acids are essential fatty 
acids present in fish and other seafood, and include eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA). 
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EPA and DHA may be also obtained from the conversion 
of essential fatty acid plant-derived α-linolenic acid, but this 
pathway does not seem to be efficient enough to produce 
adequate amounts of EPA and DHA in humans.22 Thus, to 
ensure adequate amounts of omega-3 fatty acids, fish oils, 
containing both EPA and DHA representing about 30% of 
the total fatty acids, may be used. However, due to the need 
of high doses of EPA and DHA for the pharmacological 
effect, preparations enriched with these fatty acids are also 
available.
At pharmacological doses (at least 2 g/d), omega-3 fatty 
acids significantly reduce TG levels, but may also affect other 
classes of lipids, including LDL-C.23 In fact, omega-3 fatty 
acids increase LDL-C levels, and this observation has been 
reported remarkably in subjects with very high TG levels23 
and following the use of DHA.24 This raise in LDL-C levels 
seems to be attributable to an increase of LDL size rather than 
an increase of LDL particle number, thus resulting in a shift 
from the smaller TG-rich, dense proatherogenic LDL to the 
larger, less atherogenic LDL particles.23 Other studies have 
shown that EPA increases LDL particle size without increas-
ing LDL-C levels;25,26 this may depend on the starting TG 
plasma levels and LDL subspecies distribution in the patients 
investigated. In fact, in subjects with mild-to-moderate HTG, 
the increase of LDL-C levels is less significant.23 Omega-3 
fatty acids have only a slight HDL-raising effect in HTG 
patients.23 Besides the TG-lowering properties, EPA and 
DHA improve cardiovascular hemodynamics, and reduce 
the risk of cardiovascular events, such as fatal cardiac events 
or atrial fibrillation.27
Among head-to-head studies, both EPA and DHA 
significantly reduce TG levels, but DHA demonstrated a 
greater efficacy to reduce TG compared with EPA (DHA 
from -8.0% to -43.7%; EPA from +1.8% to -34.9%).24,28 
LDL-C increased by 2.6%±4.3% with DHA treatment and 
decreased by 0.7%±4.2% with EPA; the increase in LDL-C 
levels following DHA treatment was directly associated with 
baseline TG levels.24
Several mechanisms are involved in the TG-lowering 
properties of omega-3 fatty acids. Omega-3 fatty acids 
reduce hepatic lipogenesis by inhibiting diacylglycerol 
acetyl-transferase and phosphatidic acid phosphohydrolase, 
two key enzymes involved in the synthesis of TG, thus 
decreasing TG production in the liver, and as a consequence 
of the reduced substrate availability, VLDL assembly and 
secretion.23 This effect may also be related to the reduced 
availability of substrate owing the hepatic β-oxidation of 
other fatty acids induced by omega-3 fatty acids.23 These 
effects are mainly due to the omega-3 fatty acids interaction 
with hepatic nuclear receptors, including peroxisome 
proliferators-activated receptor (PPAR) α, hepatic nuclear 
factor (HNF)-4α and LXR-α, and to the regulation of the 
transcription factor sterol regulatory element-binding protein 
(SREBP) 1c, which play a key role in the lipogenesis pro-
cess.29 Thus, the binding of omega-3 fatty acids to PPARα 
rapidly induced changes in the expression of genes involved 
in hepatic fatty acid oxidation.29,30 Omega-3 fatty acids 
inhibit hepatic fatty acid synthesis by suppressing SREBP-1c 
gene transcription and enhancing degradation of SREBP-1c 
mRNA, thus resulting in a reduced SREBP-1c nuclear 
abundance.29,30 Omega-3 fatty acids increase LPL activity in 
extrahepatic tissues, including heart and skeletal muscle, and 
also increase β-oxidation of fatty acids in skeletal muscle, 
thus contributing to the reduction of plasma TG levels.31 In 
vitro, VLDL particles enriched with omega-3 fatty acids are 
more quickly converted to LDL,32 suggesting an increased 
percentage conversion of VLDL to LDL,33,34 and explaining 
the observed increase of LDL in HTG subjects treated with 
omega-3 fatty acids.
Introduction to the management  
of HTG
Most fish oils contain high levels of EPA and DHA. The 
required doses for a significant lipid effect are at least 2 g/d 
or more; patients with severe HTG must be treated with 
2–4 g/d of omega-3 fatty acids to reduce TG by 25%–30%, 
with a higher decrease in subjects with higher baseline TG 
levels.35 For these reasons, omega-3 fatty acid intake with the 
diet, although strongly recommended, is not adequate for the 
management of high TG level subjects. Thus, concentrated 
preparations of omega-3 fatty acids have been formulated.
The first available pharmaceutical form of omega-3 was 
composed by 47% EPA and 38% DHA in their ethyl ester 
forms (OM3-EE), and was approved as an adjunct to diet for the 
treatment of severe HTG (TG $500 mg/dL, $5.65 mmol/L) 
(Table 1).36 In patients with severe HTG, OM3-EE 4 g/d 
for 16 weeks significantly decreased TG levels (-45%), 
associated with a relevant reduction of VLDL-C (-32%);35 
LDL-C and HDL-C increased significantly (+31%, 
P=0.0014 and +13%, P=0.01, respectively) (Table 2).35 
Similar results were obtained in another study in patients 
with severe HTG: 4 g/d for 6 weeks reduced TG levels by 
38.9% (P=0.001), VLDL-C by 29.2% (P=0.001), and total 
cholesterol (TC) by 9.9% (P=0.004), with concomitant raise 
in LDL-C and HDL-C (+16.7%, P=0.007 and +5.9%, P=0.57, 
respectively) (Table 2).37 As patients with high TG levels 
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often also exhibit higher non-HDL-C levels, they need to be 
treated with combination therapies that may include a statin 
to lower cholesterol and omega-3 fatty acids to lower TG.38 
When added to simvastatin therapy in patients with persistent 
HTG, OM3-EE significantly reduced TG, VLDL-C, and non-
HDL-C, compared with simvastatin alone (-29.5%, -27.5%, 
and -9.0% vs -6.3%, -7.2% and -2.2% respectively) 
(Table 2).39 Similar results were obtained when OM3-EE was 
used in association with atorvastatin (Table 2).40
A high-purity ethyl ester form of EPA (EPA-EE) 
was formulated containing $96% EPA and no DHA 
(Table 1) to avoid LDL-C increase observed with EPA/DHA 
or DHA alone, particularly in subjects with very high 
TG levels.24,41 This formulation has been approved as an 
adjunct to diet for the treatment of adults with severe HTG 
(TG $500 mg/dL, $5.65 mmol/L).42 In subjects with very high 
TG levels ($500 mg/dL and #2,000 mg/dL; $5.65 mmol/L 
and #22.60 mmol/L), with or without background statin ther-
apy (MARINE study), EPA-EE significantly decreased TG 
levels (-19.7% and -33.1% with 2 and 4 g/d, respectively), 
and improved other lipid parameters, including VLDL-C 
(-15.3% and -28.6% with 2 and 4 g/d, respectively), non-
HDL-C (-8.1% and -17.7% with 2 and 4 g/d, respectively), 
and TC (-6.8% and -16.3% with 2 and 4 g/d, respectively) 
without increasing LDL-C levels (Table 2).43 In subjects 
with baseline TG levels $750 mg/dL ($8.47 mmol/L), the 
effect of EPA-EE on TG levels was even greater (-32.9% at 
2 g/d, -45.4% at 4 g/d).43 In the ANCHOR study, EPA-EE 
was tested in statin-treated patients with persistent high TG 
levels ($500 mg/dL and #2,000 mg/dL; $5.65 mmol/L 
and #22.60 mmol/L) at 2 and 4 g/d for 12 weeks.44 TG levels 
were lowered by 10.1% and 21.5%, respectively (Table 2), 
and the reduction was even higher in subjects taking higher-
efficacy statin regimens or in subjects with higher baseline 
TG levels (at 4 g/d: -10.9% in the first tertile, -19.3% in the 
second, and -21.8% in the third tertile).44 VLDL-C, non-
HDL-C, and TC were also significantly reduced (Table 2).44 
LDL-C levels were reduced, but only at 4 g/d the decrease 
was significant (Table 2).44 The ongoing trial REDUCE-IT 
will evaluate the ability of long-term use of EPA-EE to reduce 
cardiovascular events in high-risk statin-treated patients with 
HTG compared with statin therapy alone.45
Novel formulations of omega-3  
fatty acids
To be absorbed in the intestine, the EE form of omega-3 
fatty acids must be converted into FFA by pancreatic lipase 
enzymes, largely secreted in the intestine in response to 
dietary fat intake. Thus, while the EE forms of omega-3 
fatty acids need this hydrolysis step, the FFA forms are not 
dependent on pancreatic enzyme activity and are more read-
ily absorbed.46–49 In addition, current guidelines recommend 
that patients with severe HTG follow a very low-fat diet;21,50 
this will lead to a reduced pancreatic lipase release and, as a 
consequence, to a reduced absorption of the EE formulations. 
Omega-3 carboxylic acids is the first FFA form of long-chain 
omega-3 fatty acids containing 55% EPA and 20% DHA 
(Table 1), and approved by US Food and Drug Administration 
(FDA) for the treatment of adults with severe HTG.51
Comparison of current pharma-
cological and pharmacokinetic 
studies on omega-3 fatty acid forms
After oral administration, omega-3 FFA are directly absorbed 
in the small intestine, and then enter the systemic circulation. 
Maximum EPA and DHA plasma concentrations are reached 
after 5–8 hours and 5–9 hours, respectively, after repeat daily 
dosing of 4 g OM3-FFA/d under low-fat diet conditions for 
2 weeks; steady-state plasma concentrations of  both EPA 
and DHA are reached within 2 weeks of repeat daily dos-
ing.52 Following a single dose, EPA and DHA are mainly 
incorporated in phospholipids, TG, and cholesteryl esters.52 
OM3-FFA are mainly oxidized in the liver similarly to dietary-
derived fatty acids, and are not excreted by kidneys.52
Two studies have investigated the pharmacokinetics 
of omega-3 FFA formulation. The ECLIPSE (Epanova® 
compared to Lovaza® in a pharmacokinetic single-dose 
evaluation) study evaluated the bioavailability of EPA 
and DHA from single 4 g doses of omega-3 FFAs and 
omega-3 EEs in overweight adults during low-fat or high-
fat consumption periods.53 During the low-fat period, the 
free FFA form showed a higher bioavailability for EPA + 
DHA compared with the EE form, with a baseline-adjusted 
AUC
0–t
 for EPA + DHA 4-fold higher and C
max
 3.7-fold 
Table 1 Prescription omega-3 fatty acids formulations
Formulations Description EPA and DHA content
OM3-ee Contains ePA and DHA ethyl esters 47% ePA, 38% DHA
ePA-ee Contains ePA ethyl ester (icosapent ethyl) $96% ePA
OM3-FFA Contains ePA and DHA FFAs 55% ePA, 20% DHA
Abbreviations: ePA, eicosapentaenoic acid; DHA, docosahexaenoic acid; FFAs, free fatty acids.
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higher with the FFA form compared with the EE form.53 
When analyzed separately, both EPA and DHA showed 
a higher bioavailability profile in subjects taking the FFA 
form (9.0-fold and 2.0-fold, respectively).53 Particularly 
relevant is the greater bioavailability of DHA with the 
FFA formulation during both low-fat and high-fat periods, 
although the starting amount of DHA was significantly 
lower (-42%) with the FFA formulation compared with 
Table 2 Lipid-modulating effects of available omega-3 fatty acids formulations
TG levels Clinical trial Effects
OM3-EE
HTG patients
(500–2,000 mg/dL; 5.65–22.60 mmol/L)
OM3-ee34 TG: -45%
vLDL-C: -32%
TC: -15%
LDL-C: +31%
HDL-C: +13%
HTG patients (500–2,000 mg/dL; 5.65–22.60 mmol/L) OM3-ee36 TG: -38.9%
vLDL-C: -29.2%
TC: -9.9%
LDL-C: +16.7%
HDL-C: +5.9%
Patients with persistent HTG ($200,  
,500 mg/dL; $2.26, ,5.65 mmol/L)
COMBOS study (OM3-ee + simvastatin)39 TG: -29.5% (simva: -6.3%)
vLDL-C: -27.5% (simva: -7.2%)
HDL-C: +3.4% (simva: -1.2%)
LDL-C: +0.7% (simva: -2.8%)
TC: -4.8% (simva: -1.7%)
Non-HDL-C: -9.0% (simva: -2.2%)
HTG patients ($250, ,599 mg/dL; $2.82,  
,6.76 mmol/L)
OM3-ee + atorvastatin40 TG: -45.4% (atorva: -26.9%)
vLDL-C: -54.3% (atorva: -37%)
LDL-C: -29.3% (atorva: -31.5%)
HDL-C: +12.4% (atorva: +10%)
TC: -31.5% (atorva: -27.4%)
Non-HDL-C: -40.2% (atorva: -33.7%)
EPA-EE
HTG patients ($500, #2,000 mg/dL; $5.65,  
#22.60 mmol/L)
MARiNe study43 TG: -19.7% (2 g), -33.1% (4 g)
vLDL-C: -15.3% (2 g), -28.6% (4 g)
TC: -6.8% (2 g), -16.3% (4 g)
Non-HDL-C: -8.1% (2 g), -17.7% (4 g)
LDL-C: +5.2% (2 g), -2.3% (4 g)
HDL-C: +1.5% (2 g), -3.6% (4 g)
Statin-treated patients with persistent HTG ($500,  
#2,000 mg/dL; $5.65, #22.60 mmol/L)
ANCHOR study44 TG: -10.1% (2 g), -21.5% (4 g)
vLDL-C: -10.5% (2 g), -24.4% (4 g)
TC: -4.8% (2 g), -12% (4 g)
Non-HDL-C: -5.5% (2 g), -13.6% (4 g)
LDL-C: -3.6% (2 g), -6.2% (4 g)
HDL-C: -2.2% (2 g), -4.5% (4 g)
OM3-FFA
HTG patients
($500, ,2,000 mg/dL; $5.65, ,22.60 mmol/L)
evOLve study55 TG: -25.9% (2 g), -30.9% (4 g)
vLDL-C: -26.6% (2 g), -33.0% (4 g)
TC: -5.4% (2 g), -7.5% (4 g)
Non-HDL-C: -7.6% (2 g), -9.6% (4 g)
LDL-C: +19.2% (2 g), +19.4% (4 g)
HDL-C: +7.4% (2g), +5.8% (4 g)
Statin-treated patients with residual HTG ($200, 
,500 mg/dL; $2.26, ,5.65 mmol/L)
eSPRiT study60 TG: -14.6% (2 g), -20.6% (4 g)
vLDL-C: -14.3% (2 g), -21.5% (4 g)
TC: -1.7% (2 g), -3.8% (4 g)
Non-HDL-C: -3.9% (2 g), -6.9% (4 g)
LDL-C: +4.6% (2 g), +1.3% (4 g)
HDL-C: +2.6% (2 g), +3.3% (4 g)
Abbreviations: TG, triglycerides; HTG, hypertriglyceridemia; OM3-ee, contains ePA and DHA ethyl esters; ePA-ee, contains ePA ethyl ester; OM3-FFA, contains ePA 
and DHA FFAs; ePA, eicosapentaenoic acid; DHA, docosahexaenoic acid; vLDL-C, very low density lipoproteins-cholesterol; TC, total cholesterol; LDL-C, low density 
lipoprotein-cholesterol; HDL-C, high density lipoproteins-cholesterol.
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the EE formulation.53 Altogether, these findings suggest 
a therapeutic advantage of the FFA form omega-3 during 
the treatment of subjects with severe HTG under low-fat 
diet.
The ECLIPSE II study compared the bioavailability of the 
FFA form with the EE form following repeat dosing.54 After 
14 days of treatment under a low-fat diet condition, a higher 
plasma level of EPA + DHA was found in subjects taking 
the FFA form compared with subjects taking the EE form; 
when adjusted for baseline values, the difference was even 
greater, with 5.8-fold higher in AUC
0–24h
 and 6.5-fold higher 
in C
max
.54 TG levels were reduced to a greater extent with 
the FFA form compared with the EE form (geometric least-
square means 21% and 8%, respectively; P=0.013), while 
no differences in percent change from baseline in LDL-C, 
non-HDL-C, and HDL-C were observed between the two 
treatment groups.54 These results suggest that omega-3 FFAs 
provide more EPA and DHA under low-fat diet conditions so 
that the higher bioavailability translates into a greater effect 
on plasma TG levels, and that the TG-lowering efficacy with 
the FFA form may be greater than that with the EE form at 
equivalent daily doses.
The TG-lowering efficacy of the omega-3 FFA for-
mulation has then been tested in subjects with severe 
HTG ($500 mg/dL and ,2,000 mg/dL; $5.65 mmol/L 
and ,22.60 mmol/L) at three dosages (2, 3, and 4 g/d) 
in the double-blind, randomized EVOLVE (Epanova for 
lowering very high triglycerides) trial.55 After 12 weeks, 
during which the subjects also followed the diet (low-fat 
diet) indications based on NCEP ATP III,50 fasting serum TG 
levels decreased significantly with all omega-3 FFA doses 
compared with controls (olive oil 4 g/d) (-25.9%, -25.5%, 
and -30.9% with 2, 3, and 4 g/d, respectively, vs -4.3% 
of controls) (Table 2).55 TC and non-HDL-cholesterol 
decreased in all treatment groups compared with control 
(TC: -5.4%, -4.9%, -7.5% vs +3.2%; non-HDL-C: -7.6%, 
-6.9%, -9.6% vs +2.5%);55 a significant increase of LDL-C 
was observed (+19.2%, +14.3%, +19.4% vs +3.0%) (Table 2), 
but no increase in apoB levels was reported,55 indicating no 
increase in the number of circulating atherogenic particles. 
VLDL-C and remnant lipoprotein cholesterol (RLP-C) were 
also significantly reduced in all treatment groups.55 Thus, the 
net effect was a reduction of the amount of cholesterol car-
ried by apoB-containing particles. The main finding of this 
study is that, due to its greater bioavailability, this omega-3 
formulation may have a higher efficacy at lower doses. When 
subgroups of high-risk patients with diabetes, or baseline 
TG $750 mg/dL ($8.47 mmol/L), or the highest tertile of 
apoC-III or remnant-like particle cholesterol were analyzed, 
the most significant decreases of TG and non-HDL-C levels 
were observed,56 suggesting that particular subgroups may 
benefit from the treatment with the omega-3 FFA formula-
tion. ApoC-III that plays a negative role on TG metabolism 
by inhibiting LPL activity was significantly reduced (-11%, 
-12%, and -14%, respectively, vs +1.6%),55 which may 
represent a further clinical benefit. This finding was consis-
tent with results obtained in studies with the omega-3 EE 
formulation.57,58
Omega-3 FFA treatment also reduced the levels of other 
key players in the inflammatory process, such as arachi-
donic acid (AA) and lipoprotein-associated phospholipase 
A
2
 (Lp-PLA
2
).55 AA, as a substrate of different enzymes that 
can generate several mediators involved in inflammation,59 
was reduced by 15.1%, 16.0%, and 23.2% with 2, 3, and 
4 g/d, respectively, compared with a 2.2% increase of 
controls.55 Lp-PLA
2
 that was shown to be reduced by the 
treatment with omega-3 EEs57,58 significantly decreased also 
in subjects treated with omega-3 FFA (-14.9%, -11.1%, 
and -17.2%, respectively, compared with -1.9% reduction 
of controls).55
Finally, the FFA formulation (2 or 4 g/d) has been 
evaluated in high cardiovascular risk patients treated 
with statin and with persistent HTG ($200 mg/dL 
and ,500 mg/dL; $2.26 mmol/L and ,5.65 mmol/L) in the 
Phase III ESPRIT trial (Epanova combined with a statin in 
patients with HTG to reduce non-HDL-cholesterol).60 This 
study confirmed the efficacy of FFA formulation of omega-3 
as an adjunct to statin therapy and low-diet in these patients: 
TG levels significantly decreased (-14.6% and -20.6% with 
2 and 4 g/d, respectively) compared with controls (-5.9%, 
statin + olive oil 4 g/d) (Table 2); omega-3 FFA also reduced 
TC (-1.7% and -3.8% vs +0.5%), non-HDL-C (-3.9% 
and -6.9% vs -0.9%), and VLDL-C (-14.3% and -21.5% 
vs -5.9%) (Table 2).60 When the results were analyzed based 
on statin potency, TG and non-HDL-C reductions were greater 
in patients taking high-potency statins.60 EPA and DHA 
plasma levels were significantly increased (DHA: +49.5% 
and +71.4% with 2 and 4 g/d; EPA: +188% and +348%), with 
values greater than those reported following the treatment 
with the EE formulation.60 This would be a further benefit, 
as elevated plasma omega-3 fatty acid levels are associated 
with a reduction of cardiovascular risk.61 The increased levels 
of EPA and DHA were associated with significant reductions 
of AA levels (-11.1% and -19.8%, respectively).60 LDL-C 
was observed to increase significantly (+4.6%, P,0.05) in 
the 2 g/d group, but not in the 4 g/d group.60
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The ongoing STRENGTH trial (a long-term outcomes 
study to assess statin residual risk reduction with Epanova in 
high cardiovascular risk patients with HTG) will evaluate the 
efficacy of omega-3 FFA formulation adjunct to statin therapy 
in high-risk subjects in the prevention and reduction of major 
cardiovascular events.62 This trial will assess the time to the 
first occurrence of any component of major adverse cardio-
vascular events (including cardiovascular death, nonfatal MI, 
nonfatal stroke, coronary revascularization, and hospitaliza-
tion for unstable angina). Patients will be enrolled on the basis 
of their high cardiovascular risk, having optimal LDL-C lev-
els (#100 mg/dL) but with residual atherogenic dyslipidemia 
(TG: $200 mg/dL and #500 mg/dL; HDL-C ,40 mg/dL for 
men and ,45 mg/dL for women), and will be in the study 
for up to 5 years.
Safety and tolerability of FFA form  
of omega-3
In the ECLIPSE study, both FFA and EE formulations were 
well tolerated and no serious adverse effects or death have 
been reported.53 Among all treated subjects, 53.7% subjects 
reported 51 adverse effects, but all were considered mild, 
the most common being headache, diarrhea, dizziness, and 
hyperglycemia.53 Similarly, in the ECLIPSE II study, both 
treatments were well tolerated; only one subject in the FFA 
treatment group exhibited an increase in bilirubin level and 
a decrease of neutrophil count, and the authors concluded 
that these effects were likely not related to the treatment.54 
However, previous studies showed reduced neutrophil count 
in subjects whose diet was enriched with DHA, in the absence 
of EPA,63,64 suggesting the need of further studies to clarify 
this aspect.
During the 12 weeks of treatment in the EVOLVE trial, 
omega-3 FFA were safe and generally well tolerated; the 
frequency of one or more treatment-related adverse reactions 
was higher in the omega-3 FFA treatment group compared 
with controls (40%, 43%, and 44% at 2, 3, and 4 g/d, respec-
tively, vs 26%).55 Discontinuation due to adverse events was 
5%–7%, and was mainly due to gastrointestinal effects in the 
groups treated with omega-3 FFA, while no discontinuation 
was registered in the control group.55 The most common 
adverse events reported in the groups treated with omega-3 
FFA were mild-to-moderate gastrointestinal disorders.55 
Similarly, in the ESPRIT trial, the frequency of adverse 
events related to treatment was higher in the omega-3 FFA 
groups (33.0% with 2 g/d and 41.7% with 4 g/d) compared 
with controls (27.9%).60 Gastrointestinal disorders were the 
most frequent adverse events, observed particularly in the 
group taking the higher dosage of omega-3 FFA.60 Discon-
tinuation due to treatments ranged from 0.9% in the control 
group to 3.2% in the 4 g/d group.60
Conclusion
Reducing very high TG is important for the control of risk 
of acute pancreatitis and may be helpful to reduce the risk of 
coronary heart disease, and long-chain omega-3 fatty acids 
represent an efficient tool for the management of subjects 
with high TG levels. The recent FFA formulation seems to 
be a promising therapeutic approach with the advantage of 
a higher TG-lowering efficiency at lower doses, which can 
be an important parameter to increase drug compliance. 
Ongoing trials are evaluating the efficacy of omega-3 FFA 
formulation in the prevention of cardiovascular events.
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